Jeremy Graff

Dr. Grafr brings over 20 years of experience in preclinical. clinical research and translational analysis for nOvel immune-activating therapeutics in oncology. Most recently. Dr. Graff served as Chief Development Officer and Senior Vice President. Research at HiberCell. a biotechnology company developing novel therapeutics for cancer relapse and metastasis. He led the scientiñic and clinical development teams for HiberCell. Prior to that, he was employed at Biothera Pharmaceuticals serving as President since 2018 and Chief Scientiñc Officer since 2014. In these executive roles, Dr. Graff implemented strategic translational studies along with clinical programs in immuno-oncology. He also managed corporate strategy for investor engagement and oversaw the acquisition of Biothera's lead asset Imprime PGG by HiberCell. Inc in 2020. Dr. Graff spent 16 years at Eli Lilly and Lilly Research Labs where he developed extensive experience in Cancer Drug Discovery and Development. immuno-oncology. biomarker discovery and patient stratification. During his last position at Eli Lilly as Group Leader, Cancer Biology and Patient Tailoring. he established a Translational Oncology Unit to improve the technical success of clinical trials. At Lilly Research Labs. he was the recipient of the President's Recognition Award. the Company's highest annual award. Dr. Graff received a Ph.D. from the University of Kentucky's Markey Cancer Center and completed a post-doctoral fellowship at the John Hopkins University Oncology Center. He has authored 6o peer-reviewed publications and holds a number of patents for novel cancer therapies.